Peritoneal Tumor Microenvironment of Cancers on Cancer Hallmarks. Perspectives of Translational Medicine

Table of Contents

1. What is tumor microenvironment?
2. Clinical significance in cancers
3. Tumor microenvironment of peritoneal cancer: the concept of premetastatic niche altered before tumor implantation
4. Tumorigenesis and progression of cancer
5. Histopathological features of cancer in peritoneum
6. Metabolism of cancer cells altered in peritoneal tumor microenvironment
7. Cancer stem cells: Dormancy and chemoresistance
8. Immune cells in tumor microenvironment
9. Fibroblasts in tumor microenvironment
10. Cytokine and chemokines in tumor microenvironment
11. Exosomal cell-to-cell interactions in tumor microenvironment
12. Development of diagnostic/prognostic/therapeutic biomarkers
13. Therapeutic approaches targeting tumor microenvironment
14. The concept of xenograft with difference between cancer cell (human) and microenvironment (mice)
15. Tumor organoids model for validation of biomarkers critical for cancer progression
16. Innovative technology to decipher tumoral heterogeneity of peritoneal cancers
17. Tumor evolution during chemotherapy
18. Tumor evolution during metastasis
19. Modulation of tumor microenvironment: (1) Pressure (PIPEC), hydration/temperature (Coelioscopy procedure) and light (photodynamic therapy)
20. Modulation of tumor microenvironment: (2) Surgery
21. Modulation of tumor microenvironment: (3) Radiation
22. Future perspective: Identification and validation of biomarkers using liquid biopsy

Authors

Yong Sang Song Professor, Seoul National University, College of Medicine, Seoul, South Korea. Yong Sang Song, MD, PhD is currently Professor at Seoul National University, College of Medicine. He received his MD and PhD at the Seoul National University (1983 and 1994 respectively). He was elected as the chairperson of Korean Society of Urogynecology in 2006. He was selected as the Director of Cancer Research Institute at Seoul National University in 2009, and as the President of Korean Society of Cancer Prevention in 2012. He served as the President of International Society of Precision Cancer Medicine (ISPCM) in 2018. His major research interests are molecular mechanisms of tumors, especially the role of tumor microenvironment in cancer cell metabolism, chemoresistance and precision medicine in gynecologic cancer. He is particularly interested in the impact of components of tumor microenvironment in ovarian cancer progression. Danny N. Dhanasekaran Samuel Roberts Noble Foundation Endowed Chair in Cancer Research, Deputy Director for Basic Sciences, Director, SCC-COBRE & Center for Basic Cancer Research, Stephenson Cancer Center, University of Oklahoma Health Science Center, USA. Danny N. Dhanasekaran, PhD, is Samuel Roberts Noble Foundation Endowed Chair in Cancer Research. He is Deputy Director for Basic Sciences and Director, SCC-COBRE & Center for Basic Cancer Research, Stephenson Cancer Center,?University of Oklahoma Health Science Center, USA. Danny N. Dhanasekaran, PhD, is Samuel Roberts Noble Foundation Endowed Chair in Cancer Research. He is Deputy Director for Basic Sciences and Director, SCC-COBRE & Center for Basic Cancer Research, Stephenson Cancer Center,?University of Oklahoma Health Science Center, USA. Benjamin K. Tsang Director, Reproductive Biology Unit, Professor, Department of Obstetrics and Gynaecology and Cellular & Molecular Medicine and the Interdisciplinary School of Health Sciences, University of Ottawa, Canada. Benjamin K Tsang, PhD, is director of Reproductive Biology Unit, professor of Obstetrics & Gynecology and Cellular & Molecular Medicine; Life Research Institute, Interdisciplinary School of Health Sciences, Professor Emeritus, University of Ottawa; Senior Scientist, Chronic Disease Program, Emeritus Senior Scientist, Ottawa Hospital Research Institute. Johji Inazawa Director, Bioresource Research Center, and Professor, Department of Molecular Cytogenetics, Medical Research Institute, Tokyo Medical and Dental University, Japan. Johji Inazawa, MD, PhD, is director/ specially appointed Professor, Research Core Center, Tokyo Medical and Dental University (TMDU), Emeritus Professor, TMDU, Japan. Massoud Mirshahi Professor, Research INSERM unit, Paris 7 University Paris Diderot, France. Massoud Mirshahi, MD, PhD, is Professor, Research INSERM unit, Paris 7 University Paris Diderot, France. Marc Pocard Professor, Abdominal and Oncologic Surgery, Paris 7 University Paris Diderot, France. Marc Pocard, MD, PhD, is Director Research INSERM unit, and Professor, Abdominal and Oncologic Surgery, Paris 7 University Paris Diderot, France. Ciro Isidoro Professor, Clinical Biochemistry and Clinical Molecular Biology, and Professor, Medical Oncology, Department of Health Sciences, University of Piemonte Orientale,?Italy. Professor Ciro Isidoro, Clinical Biochemistry and Clinical Molecular Biology, and Professor of Medical Oncology in the Department of Health Sciences, University of Piemonte Orientale,?Italy.